Details of the Drug

General Information of Drug (ID: DM930LE)

Drug Name
GSK4172239
Indication
Disease Entry ICD 11 Status REF
Sickle-cell disorder 3A51 Phase 1 [1]
Cross-matching ID
TTD ID
D5QR2M

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA [cytosine-5]-methyltransferase 1 (DNMT1) TT6S2FE DNMT1_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Sickle-cell disorder
ICD Disease Classification 3A51
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
DNA [cytosine-5]-methyltransferase 1 (DNMT1) DTT DNMT1 0.00E+00 2.46 4.65
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05660265) A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239D. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline